asset termination
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition
Actionable Insights Powered by AI
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition